Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
When treating esophageal cancer with post operative radiation, what, if any, are some strategies to minimize the risk of complications at the site of surgical anastomosis?
Related Questions
Given the results of ESOPEC from ASCO 2024, for which patients with resectable esophageal adenocarcinoma would you favor neoadjuvant chemoradiation?
Do you use different dose constraints for large bowel vs. small bowel?
When treating a high rectal cancer, does your coverage of the caudal mesorectum depend on the surgical plan?
What is your approach to high-grade neuroendocrine tumor of the stomach?
Would you consider SBRT to a single nodal recurrence in a patient with previously treated metastatic GEJ adenocarcinoma s/p a complete response to systemic therapy followed by 37.5 Gy to the primary who was NED for 12 months up until this recurrence?
When treating a bulky squamous cell carcinoma of the anal canal, do you try to limit the dose to the external anal sphincter to any particular number to reduce the risk of chronic fecal incontinence?
Would you dose escalate neoadjuvant radiotherapy for T3 and/or N+ rectal cancer in patients who are unwilling or unable to get chemotherapy?
Do you use more stringent liver constraints when treating HCC with SBRT in patients who are CP B8/9 or C?
In patients with T1 anal squamous cell cancer status post local excision with a close margin, would you recommend close observation or adjuvant concurrent chemoradiation?
Would you offer pelvic re-irradiation in the setting of locally recurrent anal cancer in the presacral region?
